Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Talengen International Limited is navigating 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. The portfolio's current activity is split among 4 distinct examiners and 4 distinct art units, which suggests a high degree of technical variety in their biotechnology filings. Each of the 4 pending actions is being evaluated by a different specialist in a different unit, requiring a multifaceted prosecution strategy.
The busiest examiner, SAIDHA, TEKCHAND, is currently handling 1 pending office action. With 4 total pending actions and 4 distinct examiners, the workload is distributed such that no single examiner has a dominant influence over the portfolio. This distribution across 4 distinct art units means that the company must adapt to the specific cultures and backlogs of multiple USPTO divisions. Success for Talengen International Limited will depend on successfully managing these four independent examination tracks and their respective examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAIDHA, TEKCHAND | 1 | 82.9% | +14.1% |
| BERKE-SCHLESSEL, DAVID W | 1 | 66.7% | +31.8% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
| FAN, LYNN Y | 1 | 47.3% | +49.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17798824 | METHOD AND DRUG FOR TREATING VIRAL PNEUMONIA | BERKE-SCHLESSEL, DAVID W | 259d overdue |
| 18022084 | METHOD AND DRUG FOR TUMOR TREATMENT | SAIDHA, TEKCHAND | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17798824 | METHOD AND DRUG FOR TREATING VIRAL PNEUMONIA | BERKE-SCHLESSEL, DAVID W | 259d overdue |
| 18022084 | METHOD AND DRUG FOR TUMOR TREATMENT | SAIDHA, TEKCHAND | — |
| 17793371 | METHOD FOR TREATMENT OF NERVE INJURY AND RELATED DISEASE | REYNOLDS, FRED H | — |
| 17595113 | METHOD AND MEDICINE FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | FAN, LYNN Y | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 1651 | 1 |
| 1658 | 1 |
| 1759 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18022084 | METHOD AND DRUG FOR TUMOR TREATMENT | SAIDHA, TEKCHAND | 1652 | §102§112 | Non-Final OA | — | Pending | Feb 17, 2023 |
| 17798824 | METHOD AND DRUG FOR TREATING VIRAL PNEUMONIA | BERKE-SCHLESSEL, DAVID W | 1651 | §102§103§112 | Non-Final OA | 259d overdue | Pending | Aug 10, 2022 |
| 17793371 | METHOD FOR TREATMENT OF NERVE INJURY AND RELATED DISEASE | REYNOLDS, FRED H | 1658 | §103§112DP | Non-Final OA | — | Pending | Jul 15, 2022 |
| 17595113 | METHOD AND MEDICINE FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | FAN, LYNN Y | 1759 | §103 | Final Rejection | — | Pending | Nov 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial